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A B S T R A C T
The etiology of recurrent aphthous stomatitis (RAS) remains unknown. RAS can be presented as primary,
idiopathic condition and as a secondary RAS, which is associated with a systemic disease. The aim of our study
was to evaluate the presence and concentrations of antibodies specific for celiac disease (CeD) and antibodies
related to inflammatory bowel diseases (IBD) in patients with RAS without gastrointestinal symptoms.
Antibodies against tissue transglutaminase (anti-tTG), deaminated gliadin peptides (DGP), deaminated gliadin-
analogous fragments (anti-GAF-3X) and Saccharomyces cerevisiae (ASCA) were determined by ELISA and anti-
neutrophil cytoplasmic antibodies (ANCA) by indirect immunoflurescence (IIF) in 57 patients with RAS and 60
control subjects. The prevalence of CeD specific antibodies did not differ between RAS patients and controls.
However, the concentrations of IgA anti-tTG, IgA anti-GAF-3X antibodies in patients with RAS were significantly
higher compared to controls (p=0.002 and p=0.04 respectively). Histological changes consistent with CeD
were confirmed by duodenal biopsy in one RAS patient with highly positive IgA anti-tTG, anti-GAF-3X and anti-
DGP antibodies. Higher prevalence along with higher concentrations of IgG ASCA were found in RAS patients
compared to controls (p < 0.01). Patients with positive IgG ASCA in the absence of clinical symptoms decided
not to pursue any further testing. Dysfunction of oral mucosa and the exposure to various antigens might be a
reason for the loss of tolerance resulting in increased production of autoantibodies. It seems likely that anti-
bodies are markers of aberrant immune response, rather than key effectors involved in the pathogenesis of the
disease.
1. Introduction
Recurrent aphthous stomatitis (RAS) is an inflammatory disease of
oral mucosa characterized by recurring episodes of solitary or multiple
painful aphthous ulcers. The prevalence of RAS is approximately 20%
in the general population (Jurge et al., 2006). The precise etiology of
RAS is still uncertain, but it has been proven that a number of factors
have direct influence on the RAS occurrence, including inheritance,
stress, trauma, exposure to certain food, smoking cessation, nutritional
deficiencies and hormonal imbalance. Local and systemic conditions,
immunological and microbial factors may also have a pathogenic role
(Chavan et al., 2012). RAS can be presented as primary, idiopathic
condition and as a secondary RAS, which is associated with a systemic
disease (Natah et al., 2004). The presence of refractory and recurrent
oral aphthous ulcerations could imply the existence of underlying in-
flammatory disease, such as celiac or inflammatory bowel disease
(Baccaglini et al., 2011; Lankarani et al., 2013).
Celiac disease (CeD) is a chronic small intestinal immune-mediated
enteropathy precipitated by exposure to dietary gluten in genetically
predisposed individuals (Ludvigsson et al., 2013). CeD is characterized
by the presence of autoantibodies, which are currently included in the
definition and diagnostic guidelines for CeD (Murch et al., 2013). CeD-
specific serologic markers, such as antibodies against tissue transglu-
taminase (tTG), endomysial antibodies (EMA), antibodies against dea-
minated gliadin peptides (DGP) and deaminated gliadin analogous
fragments (GAF) are considered to be a reliable diagnostic tool for CeD.
CeD can be presented with classical gastrointestinal symptoms, but also
as an atypical, silent and latent form with a wide spectrum of non-
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gastrointestinal symptoms. RAS may be one of the symptoms and it is
present as the sole manifestation in 5% of CeD patients (Shakeri et al.,
2009). On the other hand, the reported prevalence of CeD in RAS pa-
tients varies between 0%–31% (Shakeri et al., 2009; Ferguson et al.,
1976; Campisi et al., 2008; Sedghizadeh et al., 2002; Yasar et al., 2012).
The association between CeD and RAS has been evaluated in several
studies, but the supporting evidence remains equivocal (Sedghizadeh
et al., 2002; Yasar et al., 2012).
Inflammatory bowel diseases (IBD) including Crohn’s disease (CD)
and ulcerative colitis (UC) are chronic inflammatory diseases with
primary intestinal involvement. IBD patients may exhibit a wide range
of non-intestinal signs and symptoms, known as extraintestinal mani-
festations (EIM). Oral lesions can be the primary presenting signs pre-
ceding gastrointestinal symptoms in 5%–10% of affected patients
(Trikudanathan et al., 2012). Although no specific direct association
has been reported, it is assumed that 10% of patients with UC and
20%–30% of those with CD have RAS (Trikudanathan et al., 2012).
Patients with IBD and other EIMs may suffer from RAS more often than
others (Lankarni et al., 2013; Trikudanathan et al., 2012). The re-
levance of specific antibodies for IBD diagnosis is not so strong as for
CeD. Serologic markers for UC and CD are antineutrophil cytoplasmic
antibodies (ANCA) and antibodies against Saccharomyces cerevisiae
(ASCA) respectively. So far there is no evidence of association between
RAS and presence of these IBD-related antibodies.
Based on the presumed common etiopathogenesis of RAS, CeD and
IBD, which includes dysregulated mucosal immunity, the aim of our
study was to investigate the presence and concentrations of new and
accepted CeD-specific and IBD-related serologic markers in patients
with RAS free of gastrointestinal symptoms.
2. Patients and methods
2.1. Patients
The study group compromised 57 adult patients (35 males; median
age 43.7 ± 20.6, range 18–76 years) consecutively referred to the
Clinic for Periodontology and Oral Medicine, School of Dental
Medicine, University of Belgrade for management of recurrent mouth
ulcers (between April 2012 and May 2015). All patients were diagnosed
with minor RAS based on the accepted criteria (Jurge et al., 2006).
Patients’ consent was obtained for oral examination and for taking
venous blood samples.
A general medical history was taken and clinical examination was
performed on each patient. Other causes of recurrent oral ulceration
such as: systemic diseases, trauma, hematinic deficiencies and HIV in-
fection were ruled out. The exclusion criterion for Behçet's disease was
the absence of genital ulcerations, ocular and cutaneous involvement.
Also, the patients were not receiving regular treatment with drugs that
have been associated with development of RAS (Chavan et al., 2012). A
complete history was taken from all subjects regarding number of
aphthous ulcers, duration and number of attacks per year.
The control group consisted of 60 subjects as follows: 30 age- and
gender-matched healthy subjects that voluntarily accepted to partici-
pate in the study and 30 volunteer blood donors. Physical examination
and complete oral cavity examination performed in a group of 30
healthy subjects revealed the absence of any abnormality. The part of
the control group comprised of 30 volunteer blood donors was not
examined for the presence of clinical symptoms of RAS. The purpose of
the control groups was the establishment of accurate cut-off values for
autoantibodies in our population.
The Ethics Committee of the School of Dental Medicine, University
of Belgrade, Serbia, approved the study design, data collection methods
and procedure for obtaining informed consent (Approval Number 36/
13). The study was carried out according to the principles of the
Declaration of Helsinki.
Laboratory examinations were performed in the Laboratory
Department in the Clinic of Allergy and Immunology, Clinical Center of
Serbia, and in the Laboratory for Modification of Biological Response,
Department of Experimental Oncology, Institute of Oncology and
Radiology of Serbia.
Aliquots of the sera stored at −20 °C were used to detect antibody
reactivity. Serum IgA level was measured to rule out IgA deficiency.
2.2. Determination of CeD-specific antibodies
IgA and IgG antibodies against human recombinant tissue trans-
glutaminase (anti-tTG), and IgA antibodies against deaminated gliadin
analogous fragments (GAF) were evaluated by ELISA according to the
instructions of the manufacturer (Euroimmun AG, Luebeck, Germany).
The anti-GAF-3X ELISA is based on a completely new antigen which
reflects a peptide derived from native gliadin by deamidation through
tTG. The syntetic DNA coding for GAF includes threefold repetitive
modified copies of immunodominant nanopeptides cloned into a pro-
karyotic expression vector and expressed in E.coli. The cut-offs for po-
sitivity at 20 and 25 relative units per milliliter (RU/mL) for anti-tTG
and anti-GAF-3X respectively, were used in accordance with the re-
commendations of the manufacturer.
IgA and IgG antibodies against deaminated gliadin peptides (DGP)
were determined by commercial ELISA (BioSystems SA, Barcelona,
Spain). According to recommendations of the manufacturer, samples
with concentrations ≥ 10 U/mL were considered positive. Based on the
results obtained from sera of volunteer blood donors and the healthy
control group, a cut-off values (mean+2SD) were set at 12.5 U/mL for
IgA and 26 U/mL for IgG anti-DGP antibodies.
2.3. Determination of IBD-related antibodies
IgA and IgG ASCA were detected in 40 RAS patients and 30 healthy
controls by ELISA employing phosphopeptidomannan with a cut-off for
positivity at 10 U/mL (Orgentec Diagnostica, Mainz, Germany), ac-
cording to the manufacturer’s instructions.
The presence, titers and staining pattern of IgG ANCA were detected
in 57 patients with RAS and 60 controls using an indirect immuno-
fluorescence (IIF) assay with ethanol-fixed preparations of neutrophils
(Euroimmun AG, Luebeck, Germany), starting with 1:20 dilution. To
determine the serum endpoint titers, sera were diluted up to the highest
dilution that still gave the characteristic fluorescence pattern.
2.4. Statistical analysis
Statistical analyses were performed using SPSS 17.0 (SPPS Inc.
Illinois, USA). The two-tailed, parametric t-test and non-parametric Chi-
square and Mann-Whitney tests were used to test for statistically sig-
nificant differences of independent samples in two groups. Correlations
of antibody tests were assessed by Spearman’s correlation coefficient.
Values of p < 0.05 were considered significant.
3. Results
Demographic and clinical features of patients are presented at
Table 1. Patients with RAS were clinically asymptomatic for CeD and
IBD.
3.1. Prevalence of autoantibodies in RAS patients and controls
IgA or IgG anti-tTG positivity was present in 1/57 (1.8%) and IgA
anti-GAF-3X in 2/56 (3.6%) patients with RAS, which was not sig-
nificantly different from the control subjects (p > 0.05). Eleven RAS
patients (19.6%) were IgA and/or IgG anti-DGP positive comparing to
five IgA-DGP (8.3%) and eight IgG-DGP (13.3%) positive subjects in the
control group (p=0.067 and p=0.253, respectively).
The prevalence rates of IgA ASCA seropositivity did not differ
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between RAS patients and controls (3/40 vs. 3/30, p > 0.05). On the
contrary, the frequency of IgG ASCA positivity was significantly higher
in RAS patients compared to controls (8/40 vs. 0/30, p=0.009).
The prevalence of ANCA did not significantly differ between pa-
tients with RAS and controls. Namely, atypical ANCA were detected in
three patients with RAS and one healthy subject. Titers of ANCA were
low, ranged from 1:20 to 1:80.
3.2. Concentration of autoantibodies in RAS patients and controls
The concentrations of IgA anti-tTG and IgA anti-GAF-3X antibodies
in patients with RAS were significantly higher compared to con-
centrations determined amongst healthy volunteers (Mann-Whitney
test, p= 0.002 and p= 0.04 respectively) (Fig. 1 and Fig. 2).
There was also a significantly elevated concentration of IgG ASCA in
patients with RAS compared to the control group (Mann-Whitney test,
p= 0.005) (Fig. 3).
Levels of IgG and IgA anti-DGP antibodies, IgG anti-tTG and IgA
ASCA were not significantly different in RAS patients compared to
controls.
In patients with RAS IgA anti-tTG levels correlated significantly
with IgA anti-GAF-3X levels (Spearman’s coefficient of rank correlation
(ρ)= 0.36, p=0.007). In contrast, IgA anti-DGP did not correlate with
IgA tTG and IgA GAF-3X antibodies (p > 0.05).
One patient with highly positive antibodies against tTG (IgA), GAF-
3X (IgA) and DGP (IgA and IgG) in the absence of gastrointestinal
symptoms was referred to a gastroenterologist. He underwent endo-
scopic biopsy of the duodenal mucosa. Histology findings were char-
acteristic of CeD, showing villous atrophy with crypt hyperplasia and
increased intraepithelial lymphocytes (Marsh type III). A significant
improvement of stomatitis was noted after two months of gluten-free
diet. Aphthous lesions completely resolved after six months of gluten
withdrawal.
For the three patients with high levels of ASCA IgG (> 50 U/mL)
free of gastrointestinal symptoms a recommended endoscopic ex-
amination was postponed due to their doubts and fears related to the
procedure.
There were no significant associations between characteristics of
RAS, including mean duration of disease, type of ulcers, frequency of
attacks and number of lesions and concentrations of determined auto-
antibodies.
4. Discussion
It is assumed that immune-mediated mucosal damage in RAS can be
induced by various predisposing environmental factors in genetically
susceptible individuals. Oral mucosa, as a part of a gastrointestinal
tract, participate in the creation of immune tolerance to orally in-
troduced antigens, such as food and commensal microbes. It was re-
ported that RAS represents an increased risk of underlying gastro-
intestinal immunoinflammatory diseases (Ferguson et al., 1976).
Likewise, both CeD and IBD are related to inadequate mucosal immune
response to food and commensal microbe antigens (Geremia et al.,
2014; Sollid, 2002). It is believed that both CeD and IBD are ex-
acerbated by or lead to an impairment of the intestinal barrier. How-
ever, pathophysiologic mechanism, as well as clinical and therapeutic
approach, are quite distinct for these two gastrointestinal inflammatory
conditions (Murch et al., 2013; Trikudanathan et al., 2012; Geremia
et al., 2014; Sollid, 2002; Basso et al., 2014).
Anti-endomysial antibodies (EMA), anti-tTG antibodies, and anti-
bodies against deaminated gliadin peptides are considered to be specific
for CeD (Murch et al., 2013). The concentration of these antibodies has
been mostly investigated in CeD patients, while in the RAS patients
these CeD-specific antibodies have been tested only for their pre-
valence. Anti-GAF-3X antibody test based on specially designed im-
munodominant epitopes has been investigated in a few studies (de
Table 1
Demographic and clinical characteristics of patients with recurrent aphthous
stomatitis.
Demographic and diagnostic data n= 57
Gender: F/M 22/35
Age, years, mean ± SD (range) 43.7 ± 20.6
Mean disease duration (years) mean (range) 9.71 ± 11.35 (0.5-30)
Mean ulcer healing time
≤ 1 week 16 (28.1%)
> 1 week 41 (71.9%)
Frequency of attacks
3–6 attacks per year 11 (19.3%)
> 6 attacks per year 46 (80.7%)
Lesions at presentation
Solitary 12 (21.1%)
Multiple 45 (78.9%)
Fig. 1. IgA antibodies against tissue transglutaminase (tTG) in patients with
recurrent aphtous stomatitis (RAS) and healthy controls (C). Dashed line in-
dicates the cut-off for positivity.
Fig. 2. IgA antibodies against deaminated gliadin analogous fragments (GAF) in
patients with recurrent aphtous stomatitis (RAS) and healthy controls (C).
Dashed line indicates the cut-off for positivity.
Fig. 3. IgG antibodies against Saccharomyces cerevisiae (ASCA) in patients with
recurrent aphtous stomatitis (RAS) and healthy controls (C). Dashed line in-
dicates the cut-off for positivity.
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Chaisemartin et al., 2015), but none of them included RAS patients. It is
our belief that this is the first study that examined anti-GAF-3X anti-
bodies in patients with RAS. Schwertz et al. developed an ELISA based
on gliadin-related nonapeptides as a highly sensitive and specific assay
for diagnosis of celiac disease (Schwertz et al., 2004). The investiga-
tions of novel anti-GAF-3X IgA antibodies showed that they are more
sensitive and specific than anti-gliadin IgA antibodies, as provided by
the manufacturer.
In the present study, prevalence of IgA or IgG anti-tTG reactivity
was 1.8% and IgA anti-GAF-3X was 3.6% in patients with RAS, which
was not significantly different compared to control subjects. Our study
detected one new case of CeD, with severe histopathological findings in
duodenal biopsy. The prevalence of CeD in our group of RAS patients
was 1.75%, compared to 0% in matched healthy controls and 1–2% in
the general population worldwide. These data are in agreement with
previous studies (Shakeri et al., 2009; Ferguson et al., 1976;
Sedghizadeh et al., 2002; Yasar et al., 2012). Although our study found
no significant prevalence of the investigated serologic markers in RAS
patients, we have found statistically higher concentrations of IgA anti-
tTG and anti-GAF-3X antibodies, which might require further con-
sideration. Disruption of epithelial cell junctions and enhanced gluten
penetration can lead to production of antibodies against deaminated
gluten peptides in early stage of CeD, even before a significant mucosal
damage develops (Rauhavirta et al., 2014). As a marker of small bowel
mucosal damage, anti-tTG antibody levels correlate with pathological
findings in CeD patients (Donaldson et al., 2007), but still, anti-tTG
antibodies could be low or even negative in adult patients with mild
CeD (Sollid, 2002). Therefore, a negative anti-tTG antibodies in RAS
patients can not rule out the coexistence of latent or mild form of CeD.
We also found a significantly higher prevalence and elevated con-
centration of IgG ASCA in patients with RAS compared to the control
group. It has been established that patients with CD and UC are fre-
quently positive for ASCA and ANCA, respectively. Antibodies to ba-
ker’s yeast and brewer’s yeast (ASCA) have been described in up to 65%
of patients with CD (Basso et al., 2014). It has been demonstrated that
the specific antigen is a mannan localized in the yeast cell wall. The
pathogenic role of ASCAs in CD is not completely understood, but one
hypothesis links them to increased intestinal permeability (Krause and
Milo, 2004). Due to this presumed break in the epithelial integrity,
increased exposure of the mucosa to common food antigens, such as
yeasts, may result in an exaggerated antibody response.
Besides intestinal inflammatory conditions, a significantly higher
level of IgG ASCA was discovered in patients with Behçet's disease (BD)
by Krause et al. (Krause et al., 2002). Aforementioned study and an-
other study (Rhee et al., 2005) used RAS patients as a control group and
found high level of ASCA in 1/10 and 1/12 RAS patients, respectively.
Moreover, these authors also found positive correlation between titers
of IgG ASCA with the number of aphthae episodes in a year in healthy
relatives of BD patients who have RAS (Monselise et al., 2006). On the
other hand, ASCA had been found in overt CeD, as well as in early stage
of CeD, together with some other anti-microbial antibodies, suggesting
a dysregulated immune response to food and bacterial antigens. Inter-
estingly, anti-microbial antibodies and ASCA showed a decrease after
implementation of a gluten-free diet (Viitasalo et al., 2014; Conrad
et al., 2002). Conversely, a recent study found significantly increased
positivity for anti-tTG and anti-gliadin antibodies in patients with IBD
compared to controls, even if CeD could not be confirmed by histology
in any patient (Watanabe et al., 2014).
Although recent studies have suggested that imbalances in the oral
microbiota may contribute to the etiopathogenesis of RAS, no specific
bacterial species associated with RAS have been identified (Hijazi et al.,
2015). The latest findings confirm that certain bacteria species were
represented more frequently on the oral mucosa of patients with BD and
RAS, as compared to healthy controls (Seoudi et al., 2015). These
findings may or may not be linked to the similarities in ASCA produc-
tion in BD and RAS patients, but certainly indicate that mucosal
microbiome changes may play a role in the etiology of chronic mucosal
inflammatory conditions.
It is well established that oral and gut mucosal immune system
constitute an effective and dynamic network in which numerous types
of cells and molecules contribute to the balance between immune tol-
erance and immune response (Wu et al., 2014). Oral mucosa is the first
barrier of digestive system. Mucosal barrier dysfunction and the ex-
posure to various antigens can lead to modified mucosal immunity and
loss of humoral tolerance to self and microbiota antigens.
The presence of several types of antibodies in the sera of RAS pa-
tients suggests an immune mediated nature of RAS. If nothing other,
increased levels of antibodies against gliadin, t-TG and yeasts in pa-
tients with RAS might result from a common tight junction defects of
mucosal barrier similar to those already described in patients with CeD
and IBD (Fasano, 2012). It seems likely that antibodies are markers of
aberrant immune response, rather than key effectors involved in the
pathogenesis of the disease.
The low prevalence of CeD and IBD associated antibodies implies
that their determination is not generally recommended for all patients
with RAS. On the other hand, if the likelihood of gastrointestinal dis-
ease is high or aphthous stomatitis is unresponsive to conventional
treatment these tests would be useful (Shakeri et al., 2009).
Evaluation of the possible clinical significance of our findings and
elucidation of the cause-effect relationship and interactions between
CeD specific and IBD related antibodies and patients with RAS requires
a further long term follow up investigations and analysis of pro-
spectively collected serum samples from a large cohort of patients with
RAS.
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